Patents by Inventor Hans-Juergen Krause

Hans-Juergen Krause has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Formulation of human antibodies for treating TNF-? associated disorders
    Patent number: 8940305
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: January 27, 2015
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Crystalline anti-human IL-12 antibodies
    Patent number: 8940873
    Abstract: The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: January 27, 2015
    Assignee: AbbVie Inc.
    Inventors: David W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk
  • PROTEIN FORMULATIONS AND METHODS OF MAKING SAME
    Publication number: 20150023977
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Application
    Filed: October 3, 2014
    Publication date: January 22, 2015
    Applicant: ABBVIE INC.
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
  • Formulation of human antibodies for treating TNF-? associated disorders
    Patent number: 8932591
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: January 13, 2015
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Formulation of human antibodies for treating TNF-? associated disorders
    Patent number: 8916158
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: December 23, 2014
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Formulation of human antibodies for treating TNF-? associated disorders
    Patent number: 8916157
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: December 23, 2014
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Formulation of human antibodies for treating TNF-alpha associated disorders
    Patent number: 8911741
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: December 16, 2014
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20140341925
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: August 6, 2014
    Publication date: November 20, 2014
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20140341924
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: August 6, 2014
    Publication date: November 20, 2014
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Protein formulations and methods of making same
    Patent number: 8883146
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: November 11, 2014
    Assignee: AbbVie Inc.
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20140322228
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: July 2, 2014
    Publication date: October 30, 2014
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20140314781
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: July 2, 2014
    Publication date: October 23, 2014
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Formulation of human antibodies for treating TNF-? associated disorders
    Patent number: 8802101
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: August 12, 2014
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Formulation of human antibodies for treating TNF-alpha associated disorders
    Patent number: 8802100
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: August 12, 2014
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Formulation of human antibodies for treating TNF-? associated disorders
    Patent number: 8802102
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: January 3, 2014
    Date of Patent: August 12, 2014
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Formulation of human antibodies for treating TNF-alpha associated disorders
    Patent number: 8795670
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: August 5, 2014
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Crystalline anti-hTNFalpha antibodies
    Patent number: 8772458
    Abstract: The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: July 8, 2014
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Anette Koenigsdorfer, Stefan Gottschalk, Hans-Juergen Krause, Gerhard Winter, David W. Borhani, Wolfgang Fraunhofer
  • STABLE HIGH PROTEIN CONCENTRATION FORMULATIONS OF HUMAN ANTI-TNF-ALPHA-ANTIBODIES
    Publication number: 20140141008
    Abstract: The invention provides a liquid pharmaceutical formulation which does not include NaCl and comprises more than 20 mg of a polyol and at least about 100 mg/mL of a human anti-TNF-alpha antibody, or antigen-binding portion thereof. The invention provides a high concentration antibody formulation having long-term stability and advantageous characteristics for subcutaneous administration.
    Type: Application
    Filed: January 31, 2014
    Publication date: May 22, 2014
    Inventors: Wolfgang Fraunhofer, Hans-Juergen Krause, Michael Neu
  • STABLE HIGH PROTEIN CONCENTRATION FORMULATIONS OF HUMAN ANTI-TNF-ALPHA-ANTIBODIES
    Publication number: 20140141007
    Abstract: The invention provides a liquid pharmaceutical formulation which does not include NaCl and comprises more than 20 mg of a polyol and at least about 100 mg/mL of a human anti-TNF-alpha antibody, or antigen-binding portion thereof. The invention provides a high concentration antibody formulation having long-term stability and advantageous characteristics for subcutaneous administration.
    Type: Application
    Filed: January 31, 2014
    Publication date: May 22, 2014
    Inventors: Wolfgang Fraunhofer, Hans-Juergen Krause, Michael Neu
  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20140127222
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: January 3, 2014
    Publication date: May 8, 2014
    Applicant: ABBVIE BIOTECHNOLOGY LTD.
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes